ATE400264T1 - Methoden zur behandlung von nierenversagen - Google Patents

Methoden zur behandlung von nierenversagen

Info

Publication number
ATE400264T1
ATE400264T1 AT97948333T AT97948333T ATE400264T1 AT E400264 T1 ATE400264 T1 AT E400264T1 AT 97948333 T AT97948333 T AT 97948333T AT 97948333 T AT97948333 T AT 97948333T AT E400264 T1 ATE400264 T1 AT E400264T1
Authority
AT
Austria
Prior art keywords
patient
methods
ferric
accordance
kidney failure
Prior art date
Application number
AT97948333T
Other languages
English (en)
Inventor
Chen Hsing Hsu
Original Assignee
Chen Hsing Hsu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26708838&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE400264(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chen Hsing Hsu filed Critical Chen Hsing Hsu
Application granted granted Critical
Publication of ATE400264T1 publication Critical patent/ATE400264T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Liquid Crystal Substances (AREA)
  • Nonmetallic Welding Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
AT97948333T 1996-12-16 1997-11-14 Methoden zur behandlung von nierenversagen ATE400264T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3274596P 1996-12-16 1996-12-16
US08/794,328 US5753706A (en) 1996-12-16 1997-02-03 Methods for treating renal failure

Publications (1)

Publication Number Publication Date
ATE400264T1 true ATE400264T1 (de) 2008-07-15

Family

ID=26708838

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97948333T ATE400264T1 (de) 1996-12-16 1997-11-14 Methoden zur behandlung von nierenversagen

Country Status (12)

Country Link
US (1) US5753706A (de)
EP (1) EP0959878B1 (de)
JP (2) JP4173553B2 (de)
KR (1) KR100464504B1 (de)
AT (1) ATE400264T1 (de)
AU (1) AU723091B2 (de)
CA (1) CA2272711C (de)
DE (1) DE69738824D1 (de)
ES (1) ES2310417T3 (de)
IL (1) IL130041A (de)
NO (1) NO327148B1 (de)
WO (1) WO1998026776A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753706A (en) * 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
US20040020852A1 (en) * 2000-06-15 2004-02-05 Lars-Fride Olsson Method and apparatus for calcium profiling in dialysis
US6887897B2 (en) 2001-07-31 2005-05-03 Mission Pharmacal Company Calcium glutarate supplement and phosphorus binder
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
EP1655301B1 (de) * 2003-08-04 2015-03-11 Valery Khazhmuratovich Zhilov Cyclische bioisostere von purinsystemderivaten und darauf basierende pharmazeutische zusammensetzung
US6903235B2 (en) * 2003-10-08 2005-06-07 Panion & Bf Biotech Inc. Pharmaceutical-grade ferric citrate
US20060046964A1 (en) * 2004-09-02 2006-03-02 Andre Morneau Pharmaceutical formulations and methods
WO2006072054A1 (en) * 2004-12-30 2006-07-06 Genzyme Corporation Zinc-containing treatments for hyperphosphatemia
NZ566743A (en) 2005-08-18 2010-07-30 Globoasia Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
JP2009507019A (ja) * 2005-09-02 2009-02-19 ジェンザイム・コーポレーション リン酸塩を除去する方法およびそれに使用される重合体
CA2626734A1 (en) * 2005-11-08 2007-05-18 Genzyme Corporation Magnesium-containing polymers for the treatment of hyperphosphatemia
EP1978808B1 (de) * 2006-01-30 2018-08-29 Panion & BF Biotech Inc. Eisenzitrat zur umkehr, verhinderung, verzögerung oder stabilisierung einer weichgewebe-verkalkung
US7985429B2 (en) 2006-03-03 2011-07-26 C. B. Fleet Company, Inc. Flavored colonic cleansing system
US20100135950A1 (en) * 2006-07-05 2010-06-03 Genzyme Corporation Iron(II)-Containing Treatments for Hyperphosphatemia
US7998510B2 (en) 2006-08-17 2011-08-16 C. B. Fleet Company, Inc. Low dose colonic cleansing system
EP2194977A1 (de) 2007-08-31 2010-06-16 C.B. Fleet Company Incorporated Verfahren zur prävention von nephrocalcinose
WO2010045558A1 (en) * 2008-10-17 2010-04-22 Fresenius Medical Care Holdings, Inc. Method of determining a phosphorus binder dosage for a dialysis patient
KR101322259B1 (ko) * 2008-10-27 2013-10-28 에스비아이 파마 가부시키가이샤 5-아미노레불린산 혹은 그의 유도체, 또는 그들 염을 유효성분으로 하는 성인병의 예방·개선제
KR20120046753A (ko) * 2009-07-21 2012-05-10 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
US8822225B2 (en) * 2009-10-01 2014-09-02 Fresenius Medical Care Holdings, Inc. Method of calculating a phosphorus-protein ratio
WO2012005340A1 (ja) * 2010-07-07 2012-01-12 日本たばこ産業株式会社 クエン酸第二鉄を含む錠剤
MY171864A (en) * 2011-01-18 2019-11-05 Japan Tobacco Inc Iron(iii) citrate, substantially free of beta-iron hydroxide oxide
SG11201408521WA (en) * 2012-06-21 2015-01-29 Keryx Biopharmaceuticals Inc Use of ferric citrate in the treatment of chronic kidney disease patients
KR102633597B1 (ko) 2013-06-05 2024-02-06 트리시다, 인크. 경구 투여를 위한 양성자-결합 중합체
WO2015110968A1 (en) 2014-01-23 2015-07-30 Lupin Limited Pharmaceutical grade ferric citrate and method for its production
EP3157516A4 (de) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmazeutische zusammensetzungen mit eisencitrat und verfahren zur herstellung davon
IL322207A (en) 2014-12-10 2025-09-01 Tricida Inc Proton-binding polymers for oral administration
JP6206420B2 (ja) * 2015-01-13 2017-10-04 テクノサイエンス株式会社 クエン酸第二鉄を高濃度で含有するゲル状組成物の製造方法
US20180222836A1 (en) 2015-08-05 2018-08-09 Lupin Limited Process for the Preparation of Pharmaceutical Grade Ferric Citrate
IL262660B2 (en) 2016-05-06 2024-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
US10934380B1 (en) 2017-09-25 2021-03-02 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
EP4347022A1 (de) 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pädiatrische formulierungen von eisencitrat

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1131360B (de) * 1957-11-26 1962-06-14 Vitarine Company Inc Verfahren zum Stabilisieren von waessrigen Loesungen, die neben Vitamin B noch Vitamin B und Vitamin C enthalten
DE3228231A1 (de) * 1982-07-28 1984-02-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., 8000 München Arzneimittel, calciummischsalze von polymeren, anionischen carbonsaeuren und/oder schwefelsaeureestern, verfahren zu ihrer herstellung und ihre verwendung
GB2212396A (en) * 1987-12-18 1989-07-26 Procter & Gamble Dietary supplement comprising calcium and delayed release coated iron
US4970079A (en) * 1989-06-05 1990-11-13 Purdue Research Foundation Method and composition of oxy-iron compounds for treatment of hyperphosphatemia
DE4239442C2 (de) * 1992-11-24 2001-09-13 Sebo Gmbh Verwendung eines mit polynuklearen Metalloxidhydroxiden modifizierten Adsorptionsmaterials zur selektiven Elimination von anorganischem Phosphat aus proteinhaltigen Flüssigkeiten
JPH08198760A (ja) * 1995-01-20 1996-08-06 Japan Organo Co Ltd 経口用リン酸イオン吸着剤
US5753706A (en) * 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure

Also Published As

Publication number Publication date
KR100464504B1 (ko) 2004-12-31
JP2007217429A (ja) 2007-08-30
ES2310417T3 (es) 2009-01-01
CA2272711A1 (en) 1998-06-25
AU723091B2 (en) 2000-08-17
WO1998026776A1 (en) 1998-06-25
IL130041A (en) 2005-08-31
JP4173553B2 (ja) 2008-10-29
EP0959878A1 (de) 1999-12-01
NO327148B1 (no) 2009-05-04
KR20000069414A (ko) 2000-11-25
JP2001506262A (ja) 2001-05-15
DE69738824D1 (de) 2008-08-21
NO992936L (no) 1999-08-13
AU5441998A (en) 1998-07-15
EP0959878B1 (de) 2008-07-09
US5753706A (en) 1998-05-19
CA2272711C (en) 2008-04-29
IL130041A0 (en) 2000-02-29
EP0959878A4 (de) 2002-03-27
NO992936D0 (no) 1999-06-16

Similar Documents

Publication Publication Date Title
DE69738824D1 (de) Methoden zur behandlung von nierenversagen
Lockwood et al. Recovery from Goodpasture's syndrome after immunosuppressive treatment and plasmapheresis.
EP0072947B2 (de) Mittel zur Verhütung und Behandlung von Leberkrankheiten
DE69636085D1 (de) Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea
Zinberg et al. Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis.
EA199800399A1 (ru) Сульфатные конъюгаты урсодезоксихолевой кислоты и их применение в лечебных целях при воспалительных заболеваниях и других случаях
CA2150184A1 (en) Pharmaceutical composition for the treatment of inflammatory bowel diseases
Sauder et al. Acute mercury chloride inioxication. effects of hemodialysis and plasma exchange on mercury kinetic
Broughton et al. Magnesium-deficiency syndrome in burns
DE3685853D1 (de) Mittel zur behandlung von knochenkrankheiten.
EA199900609A1 (ru) Способ и фармацевтическая композиция для доставки железа у пациентов, получающих гемодиализ и перитонеальный диализ
WO2003011225A3 (en) Calcium glutarate supplement and phosphorus binder
Malluche et al. Aluminum-related bone disease
CA2344910A1 (en) Method for treating renal disease, and pharmaceutical composition for treating renal disease
Hautmann et al. Calcium oxalate stone disease: effects and side effects of cellulose phosphate and succinate in long-term treatment of absorptive hypercalciuria or hyperoxaluria
Hanno et al. KAPOSI'S ARCOMA: WITH EXTENSIVE SILENT INTERNAL INVOLVEMENT
Lacher et al. Sweating treatment for chronic renal failure
Brunner et al. Chronic Mesenteric Arterial Insufficiency Caused by Vascular Neurofibromatosis.
Bliss Calciphylaxis: what nurses need to know.
NIENHUIS Clinical peritoneal dialysis
RU2005487C1 (ru) Способ лечения бронхолегочных заболеваний
SU1454472A1 (ru) Способ лечени гнойно-фибринозного плеврита
RU2150277C1 (ru) Лечение констипации методом кишечного лаважа в.а.маткевича
RU2182003C2 (ru) Способ лечения нарушения энтерогепатической циркуляции желчи у больных с наружным дренированием желчных путей
Gibb et al. Survival in Whipple's disease

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0959878

Country of ref document: EP